BG
INO icon

BlackRock Group’s Inovio Pharmaceuticals INO Stock Holding History

BlackRock Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$232K Buy
2,789
+785
+39% +$71K ﹤0.01% 2620
2016
Q3 		$224K Buy
2,004
+81
+4% +$8.95K ﹤0.01% 2594
2016
Q2 		$213K Buy
1,923
+84
+5% +$10.2K ﹤0.01% 2562
2016
Q1 		$192K Buy
1,839
+764
+71% +$59K ﹤0.01% 2589
2015
Q4 		$86K Sell
1,075
-35
-3% -$2.79K ﹤0.01% 2729
2015
Q3 		$77K Buy
1,110
+283
+34% +$24.7K ﹤0.01% 2765
2015
Q2 		$81K Buy
827
+223
+37% +$23.8K ﹤0.01% 2803
2015
Q1 		$59K Buy
604
+214
+55% +$20.7K ﹤0.01% 2748
2014
Q4 		$43K Buy
+390
New +$47.7K ﹤0.01% 2794
2014
Q3 		– Sell
-11,657
Closed -$1.51M – 2854
2014
Q2 		$1.51M Buy
11,657
+7,363
+171% +$869K ﹤0.01% 1607
2014
Q1 		$686K Buy
+4,294
New +$616K ﹤0.01% 2135

Other funds holding INO

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock Group's INO Position: Q4 2016 in Review

BlackRock Group increased its Inovio Pharmaceuticals (INO) stake by 39% in Q4 2016, buying an estimated $71K and bringing the position to 2,789 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #2620.

BlackRock Group first reported a position in INO in Q1 2014 and has held it in 11 quarters since. The position peaked at $1.51M in Q2 2014. 125 funds tracked by Wall St. Rank hold INO as of Q4 2016.

  • BlackRock Group held 2,789 shares of Inovio Pharmaceuticals worth $232K as of Q4 2016.
  • BlackRock Group bought 785 Inovio Pharmaceuticals shares in Q4 2016, an estimated $71K.
  • Inovio Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2620 holding.
  • BlackRock Group first reported a position in Inovio Pharmaceuticals in Q1 2014 and has held it in 11 quarters since.
  • BlackRock Group's Inovio Pharmaceuticals position peaked at $1.51M in Q2 2014.
  • 125 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.